BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31692478)

  • 1. Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study.
    Dalon F; Roche N; Belhassen M; Nolin M; Pegliasco H; Deslée G; Housset B; Devillier P; Van Ganse E
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1839-1854. PubMed ID: 31692478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
    Sicras Mainar A; Huerta A; Navarro Artieda R; Monsó E; Landis SH; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
    Punekar YS; Landis SH; Wurst K; Le H
    Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation of triple therapy maintenance treatment among patients with COPD in the US.
    Simeone JC; Luthra R; Kaila S; Pan X; Bhagnani TD; Liu J; Wilcox TK
    Int J Chron Obstruct Pulmon Dis; 2017; 12():73-83. PubMed ID: 28053518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
    Perrone V; Sangiorgi D; Buda S; Degli Esposti L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
    Bengtson LGS; DePietro M; McPheeters J; Fox KM
    Ther Adv Respir Dis; 2018; 12():1753466618772750. PubMed ID: 29737943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010.
    Tsai YH; Yang TM; Lin CM; Huang SY; Wen YW
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2787-2793. PubMed ID: 29026296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study.
    Buhl R; Criée CP; Kardos P; Vogelmeier CF; Kostikas K; Lossi NS; Worth H
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2557-2568. PubMed ID: 30197512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exacerbation Frequency And Eosinophil Counts Among Patients With COPD Currently Prescribed Triple Therapy.
    Benson VS; Pascoe KC; Siddall J; Small M; Müllerová H
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2711-2723. PubMed ID: 31819403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease.
    Palli SR; Buikema AR; DuCharme M; Frazer M; Kaila S; Juday T
    J Comp Eff Res; 2019 Nov; 8(15):1299-1316. PubMed ID: 31559852
    [No Abstract]   [Full Text] [Related]  

  • 11. Symptomatic burden of COPD for patients receiving dual or triple therapy.
    Chen S; Small M; Lindner L; Xu X
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1365-1376. PubMed ID: 29731624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.
    Roberts MH; Dalal AA
    Int J Chron Obstruct Pulmon Dis; 2012; 7():221-33. PubMed ID: 22500122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.
    Edwards SC; Fairbrother SE; Scowcroft A; Chiu G; Ternouth A; Lipworth BJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2851-2858. PubMed ID: 27920512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease.
    Souliotis K; Silva Miguel L; Hillas G; Borges M; Papageorgiou G; Viana D; Malhadeiro J; Soulard S
    Ther Adv Respir Dis; 2020; 14():1753466620926802. PubMed ID: 32519591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
    Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reasons for triple therapy in stable COPD patients in Japanese clinical practice.
    Miyazaki M; Nakamura H; Takahashi S; Chubachi S; Sasaki M; Haraguchi M; Terai H; Ishii M; Fukunaga K; Tasaka S; Soejima K; Asano K; Betsuyaku T;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1053-9. PubMed ID: 26082629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open triple therapy for chronic obstructive pulmonary disease: Patterns of prescription, exacerbations and healthcare costs from a large Italian claims database.
    Calabria S; Ronconi G; Dondi L; Piccinni C; Pedrini A; Esposito I; Pistelli R; Martini N
    Pulm Pharmacol Ther; 2020 Apr; 61():101904. PubMed ID: 32092473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study on medical utilization and costs of chronic obstructive pulmonary disease with good lung function.
    Lim JU; Kim K; Kim SH; Lee MG; Lee SY; Yoo KH; Lee SH; Jung KS; Rhee CK; Hwang YI
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2711-2721. PubMed ID: 28979113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
    Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.